Equities research analysts at BMO Capital Markets initiated coverage on shares of Astrazeneca PLC (NYSE:AZN) in a report issued on Wednesday. The brokerage set an “outperform” rating and a $38.00 price target on the stock. BMO Capital Markets’ price target indicates a potential upside of 19.16% from the company’s current price.

Other analysts have also issued research reports about the company. Piper Jaffray Companies reaffirmed a “buy” rating on shares of Astrazeneca PLC in a research note on Wednesday, August 9th. Investec raised Astrazeneca PLC from a “hold” rating to a “buy” rating in a research note on Wednesday, August 9th. Argus reaffirmed a “buy” rating and set a $35.00 price objective on shares of Astrazeneca PLC in a research note on Friday, September 1st. Natixis raised Astrazeneca PLC from a “neutral” rating to a “buy” rating in a research note on Wednesday. Finally, Morgan Stanley lowered Astrazeneca PLC from an “overweight” rating to an “equal weight” rating in a research note on Friday, July 28th. Four analysts have rated the stock with a sell rating, eleven have given a hold rating and thirteen have given a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $33.60.

Astrazeneca PLC (NYSE:AZN) opened at 31.89 on Wednesday. The stock has a market cap of $80.75 billion, a price-to-earnings ratio of 20.92 and a beta of 0.74. The stock’s 50 day moving average price is $30.25 and its 200 day moving average price is $31.60. Astrazeneca PLC has a 12-month low of $25.55 and a 12-month high of $35.60. Astrazeneca PLC also was the target of some unusual options trading on Wednesday. Traders bought 8,259 put options on the company. This is an increase of approximately 1,510% compared to the average volume of 513 put options.

Astrazeneca PLC (NYSE:AZN) last posted its quarterly earnings data on Thursday, July 27th. The company reported $0.87 EPS for the quarter, beating analysts’ consensus estimates of $0.41 by $0.46. The business had revenue of $5.05 billion for the quarter, compared to analyst estimates of $5.04 billion. Astrazeneca PLC had a return on equity of 35.90% and a net margin of 17.80%. The business’s revenue for the quarter was down 9.9% compared to the same quarter last year. During the same quarter last year, the company earned $0.83 earnings per share. Analysts forecast that Astrazeneca PLC will post $1.85 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This report was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this report on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark laws. The legal version of this report can be accessed at https://www.thecerbatgem.com/2017/09/08/astrazeneca-plc-azn-coverage-initiated-at-bmo-capital-markets.html.

Large investors have recently made changes to their positions in the stock. PVG Asset Management Corp purchased a new stake in shares of Astrazeneca PLC during the 1st quarter valued at about $8,242,000. Liberty Mutual Group Asset Management Inc. purchased a new stake in shares of Astrazeneca PLC during the 1st quarter valued at about $890,000. Oppenheimer Asset Management Inc. purchased a new stake in shares of Astrazeneca PLC during the 1st quarter valued at about $12,038,000. Stifel Financial Corp raised its holdings in shares of Astrazeneca PLC by 53.2% during the 1st quarter. Stifel Financial Corp now owns 360,447 shares of the company’s stock valued at $11,242,000 after buying an additional 125,093 shares during the period. Finally, Parkside Financial Bank & Trust raised its holdings in shares of Astrazeneca PLC by 1.3% during the 1st quarter. Parkside Financial Bank & Trust now owns 7,040 shares of the company’s stock valued at $219,000 after buying an additional 90 shares during the period. Institutional investors and hedge funds own 14.18% of the company’s stock.

Astrazeneca PLC Company Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Analyst Recommendations for Astrazeneca PLC (NYSE:AZN)

Receive News & Stock Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related stocks with our FREE daily email newsletter.